Highlights from the 15th St Gallen International Breast Cancer Conference 15–18 March, 2017, Vienna: tailored treatments for patients with early breast cancer

Abstract

The 15th St Gallen International Breast Cancer Conference was held in Vienna for the second time, from 15th–18th March 2017. 4000 people from 105 countries all over the world were invited to take part in the event. The real highlight of the conference was the last day with the International Consensus Session which was chaired by around 50 experts on breast cancer worldwide. With reference to data from scientific research, the consensus panel tried to offer guidelines for the management of breast cancer with the aim of providing patients with optimal treatment. The topics covered focused on the treatment of breast cancer, consideration of surgery, radiotherapy, neo-adjuvant, and adjuvant systemic therapy for breast cancer, as well as genetics and prevention of breast cancer.In particular, in terms of precision medicine, an important topic of the conference was ‘is it possible to think that it could become routine in clinical practice to use immunotherapy and targeted therapy based on genetic signatures?’In view of personalised therapy, it is important to take into consideration women’s treatment preferences. It is also important not only to offer guidelines which help breast cancer experts all over the world to choose the proper treatment for women with breast cancer but also to discuss the pros and cons of the therapy with the patient. This allows for a better understanding of the disease.‘From the maximum tolerable to the minimum effective treatment: it is essential to escalate treatment when necessary and to de-escalate when unnecessary’. These few words could summarise the meaning of the 15th St Gallen International Breast Cancer Conference. Prof Martine Piccart-Gebhart was awarded with the St Gallen International Breast Cancer Award 2017 for her fundamental clinical research contribution and Prof Giuseppe Curigliano with the Umberto Veronesi Memorial Award which aims to recognise a physician’s leading role in advancing the science and care of breast cancer patients. Curigliano, in his lecture, spoke about the revolutionary immunotherapy in the clinical management of breast cancer (BC). For the development of these therapies, it is necessary to identify the genetic determinants of BC immune phenotypes in which The Cancer Genome Atlas (TCGA) has contributed towards this.For example, the T helper (Th-1) phenotype (ICR4), which also exhibits upregulation of immune-regulatory transcripts (eg. PDL1, PD1, FOXP3, IDO1, and CTLA4), was associated with prolonged patients’ survival. Chromosome segment 4q21, which includes genes encoding the Th-1 chemokines CXCL9-11, was significantly amplified only in the immune favourable phenotype (ICR4). The mutation and neo-antigen load progressively decreased from ICR4 to ICR1 but could not explain immune phenotypic differences. Mutations of TP53 were enriched in the immune favourable phenotype (ICR4). Instead, the presence of MAP3K1 and MAP2K4 mutations were closely associated with an immune unfavourable phenotype (ICR1). Using both the TCGA and the validation dataset, the degree ...

Ten‐year recurrence rates for breast cancer subtypes in the Netherlands: A large population‐based study

“…Studies have shown that the combined expression levels of ER, PR and HER2 into so‐called intrinsic molecular subtypes increases its prognostic and predictive value . The classification of tumours into luminal A, luminal B, HER2 positive and triple negative disease has been accepted by international panels that emphasise the importance to base therapeutic decisions on intrinsic molecular subtypes of breast cancer . Due to lacking data on gene expression levels, many studies use information on ER, PR and HER2 status which is based on immunohistochemistry to classify patients according to breast cancer subtypes.…”

Active Behavior of Triple-negative Breast Cancer With Adipose Tissue Invasion: A Single Center and Retrospective Review

“…Meanwhile, a thoroughgoing estimation of a patient's prognosis is crucial to avoid overtreatment and that biological understanding helps us to escalate and de-escalate therapy even in high risk tumors 20 . In TNBC, few patients suffer recurrence between 5 and 10 years after surgery, and it is unlikely that chemotherapy exerts any major impact on late recurrence 21 .…”

Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification

“…Furthermore, the observation that FISH equivocal cases do not always reflect HER2 overexpression might suggest the growing need to carefully select patients who can benefit from HER2 targeted treatment. These concerns were widely debated during the 15th St Gallen International Breast Cancer Conference [ 46 ]. A randomised phase III trial, NSABP B47 is ongoing and will probably elucidate the best treatment approach for these patients.…”